Carter Donald M, Bloom Chalise E, Kirchenbaum Greg A, Tsvetnitsky Vadim, Isakova-Sivak Irina, Rudenko Larisa, Ross Ted M
Vaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL, USA.
PATH, Washington, DC, USA.
Vaccine. 2015 Jan 1;33(1):108-16. doi: 10.1016/j.vaccine.2014.11.008. Epub 2014 Nov 18.
In 2013, avian H7N9 influenza viruses were detected infecting people in China resulting in high mortality. Influenza H7 vaccines that provide cross-protection against these new viruses are needed until specific H7N9 vaccines are ready to market. In this study, an available H7N3 cold-adapted, temperature sensitive, live attenuated influenza vaccine (LAIV) elicited protective immune responses in ferrets against H7N9 viruses. The H7N3 LAIV administered alone (by intranasal or subcutaneous administration) or in a prime-boost strategy using inactivated H7N9 virus resulted in high HAI titers and protected 100% of the animals against H7N9 challenge. Naïve ferrets passively administered immune serum from H7N3 LAIV infected animals were also protected. In contrast, recombinant HA protein or inactivated viruses did not protect ferrets against challenge and elicited lower antibody titers. Thus, the H7N3 LAIV vaccine was immunogenic in healthy seronegative ferrets and protected these ferrets against the newly emerged H7N9 avian influenza virus.
2013年，在中国检测到有人感染甲型H7N9禽流感病毒，导致高死亡率。在特定的H7N9疫苗上市之前，需要有能对这些新病毒提供交叉保护的H7流感疫苗。在本研究中，一种现有的甲型H7N3冷适应、温度敏感、减毒活流感疫苗（LAIV）在雪貂体内引发了针对H7N9病毒的保护性免疫反应。单独给予甲型H7N3 LAIV（通过鼻内或皮下给药）或采用甲型H7N9灭活病毒进行初免-加强免疫策略，均产生了高血凝抑制（HAI）效价，并使100%的动物免受H7N9攻击。未接触过疫苗的雪貂被动给予来自感染甲型H7N3 LAIV动物的免疫血清也得到了保护。相比之下，重组血凝素（HA）蛋白或灭活病毒不能保护雪貂免受攻击，且产生的抗体效价较低。因此，甲型H7N3 LAIV疫苗在健康的血清阴性雪貂中具有免疫原性，并能保护这些雪貂免受新出现的甲型H7N9禽流感病毒感染。
